A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Margetuximab-Cmkb (MARGENZA)

HER2/neu Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-01-15
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Margetuximab-Cmkb used for?

Margetuximab-Cmkb is a HER2/neu Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Margetuximab-Cmkb?

No. Margetuximab-Cmkb is brand-only with no generic equivalents currently in market.

How much does my plan pay for Margetuximab-Cmkb?

NADAC pricing data not currently available for this drug.

Is Margetuximab-Cmkb on the FDA shortage list?

No. Margetuximab-Cmkb is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

HER2/neu Receptor Antagonist6 alternatives in D1
01
Ontruzant
HER2/neu Receptor Antagonist
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Pertuzumab
Brand: PERJETA
Lowest NADAC
0Generic mfrs
$16.6MCY24 Part D spend
Compare →
03
Trastuzumab
Brand: HERZUMA
Lowest NADAC
0Generic mfrs
$7.2MCY24 Part D spend
Compare →
04
Trastuzumab-Anns
Brand: Kanjinti
Lowest NADAC
0Generic mfrs
$2.3MCY24 Part D spend
Compare →
05
Trastuzumab-Dkst
Brand: OGIVRI
Lowest NADAC
0Generic mfrs
$1.8MCY24 Part D spend
Compare →
06
Trastuzumab-Qyyp
Brand: Trazimera
Lowest NADAC
0Generic mfrs
$18.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.